Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
This trial is a single-arm study. The purpose of the trial is to evaluate the efficacy and safety of chidamide and fulvestrant in HR+/HER2- breast cancer that has failed prior adjuvant endocrine therapy with CDK4/6 inhibitors.
Hormone Receptor-positive Advanced Breast Cancer
DRUG: chidamide combined with fulvestrant
ORR, The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1), max 6 months
PFS, time to progressive disease (according to RECIST1.1), Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 1 years)|CBR, The percentage of subjects with CR+PR+SD and last more than 24 weeks in all of the participants., max 6 months|DOR, Duration of Overall Response.The date of the first assessed PR/CR (according to RECIST 1.1) to the date of the first assessed tumor progression (according to RECIST 1.1) or death from any cause., max 6 months
The study was a single-center, single-arm, open trial design. Twenty-three patients with advanced HR+/HER2- breast cancer who had failed previous adjuvant treatment with CDK4/6 inhibitors in combination with endocrine therapy were treated with fulvestrant and chidamide.